Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to sign a written consent form agreeing to take part in the study.
• People aged between 18 and 70 years old at the time of joining the study.
• People who are generally well or have only mild limitations in daily activity, as measured by a standard cancer fitness scale (ECOG score of 0 or 1).
• People whose colorectal cancer has been confirmed by a tissue biopsy (laboratory test on a tumour sample).
• People whose colorectal cancer has spread to both sides of the liver only, cannot be surgically removed, and this has been agreed upon by a team of medical specialists.
• People who have already had their primary (original) colorectal tumour surgically removed following standard cancer surgery guidelines, with an appropriate cancer stage recorded.
• People for whom at least 12 months have passed since their original colorectal tumour was removed.
• People whose original tumour was at a certain stage of spread (stage T3N1 or lower). If more than 2 years have passed since the original tumour was removed, people with a slightly more advanced tumour stage (T4N0 or T4N2) may also be considered (confirm with trial site).
• People who show no signs of cancer spread outside the liver, confirmed by specialised scans (PET/CT scan, CT scan, and pelvic MRI).
• People who have received chemotherapy treatment for at least 3 months, and no more than two different chemotherapy regimens containing a specific type of drug (fluoropyrimidine-based), which may have been combined with other chemotherapy medicines or targeted therapies.
• People whose liver tumours have remained stable or have partially shrunk during treatment, based on standard medical measurement guidelines, with this assessed at least 3 months after the most recent treatment and just before entering the study.
• People whose blood level of a cancer marker called CEA is 80 µg/L or below, measured just before entering the study.
• People whose blood test results show kidneys, platelets, and infection-fighting white blood cells are all functioning within acceptable ranges for this study.
• People who experienced liver problems after their original surgery due to an underestimation of usable liver volume may still be considered, provided they meet all inclusion criteria and none of the exclusion criteria (confirm with trial site).

Who may not be able to join:

• People whose largest liver tumour measures more than 5.5 cm just before entering the study.
• People who have Lynch Syndrome, an inherited condition that increases cancer risk.
• People whose cancer has a specific genetic change called a BRAF mutation, or whose original tumour showed a feature called microsatellite instability (MSI).
• People whose original colorectal cancer has come back, confirmed by a camera examination of the bowel (colonoscopy) or pelvic MRI within the 12 months before entering the study.
• People who have had another cancer within the past 5 years. People whose previous cancer was fully cured more than 5 years ago, or who had a type of skin cancer called basal cell carcinoma that was treated, may still be considered.
• People with substance use issues, or medical, psychological, or social circumstances that could affect their ability to take part in or complete the study.
• People with uncontrolled heart or lung conditions that would make any surgical procedure unsafe.
• People with an active infection at the time of joining.
• People who are pregnant or currently breastfeeding.
• People whom the medical team running the trial considers unsuitable to participate, for any reason.

Important: Always verify eligibility with the trial site directly before applying.